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JC virus (JCV) DNA replication occurs in the nuclei of infected cells. The level of JCV genome
expression depends on nucleotide sequences in the viral regulatory region and their interaction
with host-cell nuclear transcription factors. Our previous studies showed a higher level of NF-1X
in JCV-permissive cells compared with the other members of the NF-1 family, NF-1A, B and C,
which suggests that NF-1X plays a positive role in JCV multiplication. It remained unclear whether
a reduction in the level of NF-1A, which is expressed abundantly in JCV-non-permissive cell types,
leads to an increase in JCV multiplication. In this study, we show that downregulation of NF-1A
expression in JCV-non-susceptible progenitor and HeLa cells results in a reversion to
susceptibility for JCV multiplication. These data demonstrate that a higher level of NF-1A protein
in JCV-non-permissive cell types, compared with the level of NF-1X, may be acting as a negative
regulator at the JCV promoter to control JCV multiplication.
The human polyomavirus JC virus (JCV) is responsible for
central nervous system (CNS) demyelination leading to
progressivemultifocalleukoencephalopathy(PML)(Astrom
et al., 1958). Serological studies suggest that approximately
70% of the adult population worldwide have experienced
primaryJCVinfection(Walker& Padgett,1983;Hamiltonet
al., 2000). PML almost invariably follows from reactivation
of latent JCV in patients with compromised cellular
immunity (Berger & Major, 1999), particularly in patients
with HIV/AIDS, but also occurs in those with leukaemia,
lymphoma and connective tissue diseases. Individuals that
receive immunomodulatory therapy for autoimmune dis-
orders may also develop PML (Yousry et al., 2006). The
molecular regulation of JCV expression limits the range of
cell types that can serve as sites of JCV latency and
reactivation (Imperiale & Major, 2007). The cellular host
range of JCV depends upon a number of factors: attachment
of the virus on a host cell, virus internalization and
transport, uncoating and delivery of the viral genome, viral
DNA transcription, viral protein propagation, virus assem-
bly and virus release. Nuclear transcription factors, which
play fundamental roles in regulating JCV multiplication,
exist at the centre of these molecular pathways.
Host-cell nuclear transcription factors are required for the
activation of the JCV promoter/enhancer (Nathanson et
al., 1997; Raj & Khalili, 1995). Nucleotide sequences that
act as transcriptional promoters are located immediately
upstream of the origin of DNA replication (Delbue et al.,
2005; Nathanson et al., 1997). These sequences include the
TATA box and binding sites for Sp1, YB1, sup2, Pur-a and
NF-1. The NF-1 site is directly adjacent to an AP-1 or c-
jun/c-fos site (Ciappi et al., 1999; Ravichandran et al.,
2006). The nuclear transcription factor recognition sites are
duplicated in the tandem repeat arrangement found in JCV
isolates that support viral expression in permissible cells
(Delbue et al., 2005). These transcription factors are
required for activation of the JCV promoter/enhancer.
Cell-specific expression of JCV has been associated with
several transcription factors, but the mechanisms through
which the JCV promoter is controlled by these transcrip-
tion factors are poorly understood.
The nuclear transcription factor NF-1 is an example of a cell-
specific regulator of JCV promoter/enhancer activity (Chen
& Khalili, 1995). The NF-1 transcription family of DNA-
binding proteins (NF-1A, NF-1B, NF-1C and NF-1X) is
encodedbyfourgenes(Gronostajski,2000;Kruseetal., 1991;
Kruse & Sippel, 1994; Sumner et al., 1996). Many NF-1-
binding sites are found inthe JCV promoter/enhancerregion
(Amemiya et al., 1992; Ciappi et al., 1999; Jeang et al., 1987;
Tamura et al., 1988). Products of the four NF-1 genes form
homo- and heterodimers that bind to the canonical NF-1-
bindingsitewithapparentlyidenticalaffinities(Gronostajski,
2000). Mutations in the NF-1-binding sites reduce JCV
expression (Amemiya et al.,1 9 8 9 ) .W eh a v es h o w n
previously that the level of expression of NF-1 proteins
differs in JCV-permissive and -non-permissive cells(Messam
et al., 2003). Human progenitor-derived astrocyte cells that
support JCV infection expressed high levels of NF-1X when
compared with the non-permissive cell line HeLa. JCV-
susceptible cells showed higher levels of NF-1X and lower
levels of NF-1A compared with JCV-non-susceptible cells.
While all NF-1 proteins appear to bind to the same DNA
sequence, differences in function among NF-1 gene
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promoters of several genes were shown to be activated by
NF-1 proteins (Bisgrove et al., 2000; Jones et al., 1987;
Shaul etal., 1986).Genesthat are negatively regulated byNF-
1 also exist (Fazi et al., 2005; Kleene et al., 2001; Wong et al.,
2007). Since NF-1A is shown to function as a negative
regulator of many genes, the current study aims todetermine
whether higher levels of NF-1A expressed in JCV-non-
susceptible cells act as a negative regulator for JCV
multiplication. We used different techniques to decrease
the level of NF-1A in JCV-non-susceptible cell types and
observed an increase in JCV multiplication. This indicates an
essential negative regulatory role of NF-1A in JCV tropism.
Human brain-derived progenitor cells (referred to here as
progenitors) were obtained from the telencephalon of an 8-
week gestational fetal brain, in accordance with NIH
guidelines as described previously (Messam et al., 2003).
Progenitor cultures grown at 10–40% confluence were at
least 98% positive for nestin staining and did not express
glial fibrillary acidic protein (GFAP). Differentiation of
progenitors into an astrocytic lineage (referred to as
progenitor-derived astrocytes; PDA) was initiated by culture
medium substitution as described before (Messam & Major,
2000). HeLa cellswere grownwithMEM supplementedwith
10% fetal bovine serum. For induction of TGF-b1
signalling, cultures were treated with 5 ng recombinant
TGF-b1m l
21 (R&D Systems). Progenitor, PDA or HeLa
cultures were exposed to JCV (Mad-4 variant) at 100
haemagglutination units (HAU) per 5610
5 cells in a
minimal covering of appropriate serum-free medium.
After overnight JCV exposure, cultures were washed and
replenished with appropriate fresh media. All JCV-exposed
cultures were processed 4 days after JCV exposure.
siRNA against NF-1A or NF-1B (Dharmacon) or control
siRNA (SantaCruz) (final concentration of 10 nM) was
used to transfect cells using appropriate nucleofector
reagents (Amaxa, Inc.). Human miR-223 (hsa-miR-223;
Dharmacon) was transfected into progenitor cells (final
concentration 10 nM) using nucleofector reagent (Amaxa,
Inc.). At 16 h post-transfection, the culture medium was
replaced with fresh medium containing JCV at 100 HAU
per 5610
5 cells. After 8 h of JCV exposure, viral medium
was removed by aspiration, the cells were washed once and
fresh medium was added.
Four days after the transfection (3 days after JCV
exposure), nuclear fractions or whole-cell lysates were
prepared for use in Western blot experiments with
appropriate antibodies as described before (Ravichandran
et al., 2007). The antibodies used were: anti-JCV-VP-1
(rabbit polyclonal antibody developed in our laboratory),
anti-JVC-VP-1 (monoclonal; Novocastra), anti-SV40 T-
antigen (Oncogene), anti-b-actin (Sigma), anti-NF-1A
(Geneka/Active Motif), anti-NF-1B (Geneka/Active
Motif) and anti-NF-1X (Geneka/Active Motif). Bound
primary antibodies were detected using either an anti-
rabbit or anti-mouse horseradish peroxidase-conjugated
secondary antibody combined with the SuperSignal West
Pico Chemiluminescent substrate kit (Pierce), according to
the manufacturer’s protocol.
RT-PCR was performed as follows. Four days after the
transfection of miR-223 into progenitor cells, total RNA
was isolated using the RNeasy total RNA isolation system
(Qiagen) followed by treatment for 60 min with DNase I
[10 U (mg RNA)
21; Boehringer Mannheim]. First-strand
cDNA synthesis was performed on 1 mg total RNA using
oligo dT primers and Superscript II reverse transcriptase
(Invitrogen). cDNA product (2 ml) served as the template
for specific PCR amplification. The PCR primers for NFI-A
were 59-GTCAGCTTCACTTGGCTGGC (59 primer) and
59-AGCTTTATCTTTCCGTAACTTGGCCCGGATATCA-
AGGCCAAGTTACGGAAAGATATCG (39 primer). PCR
amplification consisted of 30 cycles of 30 s at 95 uC, 30 s at
55 uC and 1 min at 72 uC using a Perkin-Elmer 2400
thermal cycler. PCR products (20 ml) were subjected to
1.5% agarose gel electrophoresis, stained with ethidium
bromide and photographed.
Four days after the transfection of miR-223 into progenitor
cells (3 days after JCV exposure) or 4 days after treatments
with or without TGF-b1, HeLa cells grown with JCV on
chamber slides were fixed with 4% paraformaldehyde in
PBS for 20 min at room temperature and permeabilized
with 0.2% Triton in PBS for 10 min at room temperature.
Blocking, probing and visualization were done as described
previously (Ravichandran et al., 2007).
Because of the differentiation of JCV-non-susceptible
progenitors into JCV-susceptible PDAs, we examined the
role of NF-1 protein levels in these cell types.
Differentiation of progenitor cells into PDA was accom-
panied by a gradual increase in the level of NF-1X. Notably,
levels of NF-1A and NF-1B decreased (Fig. 1a). Our
observation that progenitor cells express very low levels of
NF-1X protein supports our previous study, which showed
an essential role of NF-1X protein in JCV multiplication.
The abundance of NF-1A and NF-1B in progenitor cells as
well as other JCV-non-susceptible cells (i.e. HeLa cells,
progenitor-derived neurons) raised the possibility of a
negative regulatory role of NF-1A and NF-1B in these cell
types. An earlier study showed that, following the addition
of TGF-b1, JCV multiplication increased (Ravichandran et
al., 2007). As an extension of this observation, we also
observed a decrease in NF-1A and NF-1B levels under these
conditions in progenitor cells (Fig. 1b). No increase in the
level of NF-1X was observed, however (not shown). These
results raised the possibility that NF-1A and/or NF-1B may
be acting as negative regulators for JCV multiplication. To
address the mechanism through which NF-1A and/or NF-
1B suppresses the multiplication of JCV in non-susceptible
cells, progenitors were transfected with siRNA correspond-
ing to NF-1A or NF-1B. Interestingly, the NF-1A siRNA
reduced the level of NF-1A in progenitor cells and
increased JCV multiplication, as measured by the level of
VP-1 protein. However, the reduction in NF-1B by NF-1B
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(Fig. 1c). In addition, the reduction in the level of NF-1A
led to an increase in NF-1B. Conversely, an increase in NF-
1A led to a decrease in NF-1B.
To examine the negative role of NF-1A in JCV multiplica-
tion, another JCV-non-susceptible cell type, HeLa, was
studied. Addition of TGF-b1 to HeLa in the presence of
JCV showed increased JCV multiplication, as observed by
increased VP-1 protein in immunofluorescence experi-
ments (Fig. 2a) as well as in a Western blot (Fig. 2b).
Further, the reduction of the level of NF-1A protein in
HeLa cells by siRNA resulted in JCV multiplication
(Fig. 2c). Based on the observation by Fazi et al. (2005)
that miR-223 regulates the NF-1A protein level, we
Fig. 1. (a) Comparative Western blots utilizing anti-NF-1 protein
antibodies with nuclear extracts of progenitors (Prog.) and PDAs at
the time points indicated. Aliquots (5–7 mg protein equivalent) of
nuclear extracts were resolved on 4–12% gradient gels,
transferred to PVDF membrane and probed with anti-NF-1A,
anti-NF-1B, anti-NF-1X and anti-b-actin antibodies. b-Actin was a
consistent immunoblot loading control for nuclear extracts. (b)
Effect of TGF-b1 on the level of NF-1A protein in progenitors.
Progenitors were exposed to JCV for 4 days in the presence or
absence of TGF-b1. Aliquots (5 mg protein equivalent) of nuclear
extracts were resolved on 4–12% gradient gels, transferred to
PVDF membrane and probed with anti-NF-1A, anti-NF-1B, anti-
VP-1 and anti-b-actin antibodies. (c) Effect of NF-1 proteins on
JCV multiplication. Progenitors were transfected with siNF-1A,
siNF-1B or scrambled control siRNA (Cont.). At 16 h post-
transfection, the culture medium was replaced with fresh medium
containing JCV and, after 8 h exposure to JCV, the medium was
removed by aspiration, cells were washed once and fresh medium
was added. Four days after the transfection (3 days after JCV
exposure), nuclear fractions were prepared for use in Western blot
experiments with appropriate antibodies.
Fig. 2. Effect of TGF-b1 on JCV multiplication in HeLa cells. (a)
Immunostaining of HeLa cell cultures 4 days after JCV exposure
and also with the addition of 5 ng TGF-b1m l
”1. Cells were fixed
and permeabilized and then stained with anti-VP-1 (red) to
determine relative JCV activity. Cellular nuclei were stained with
DAPI (blue). (b) Western blots, from separate experiments under
culture conditions identical to those used for immunostaining, of
nuclear extracts that were resolved on 4–12% gradient gels,
transferred to PVDF membrane and probed with anti-VP-1 and
anti-b-actin. (c) HeLa cells were transfected with NF-1A siRNA or
with scrambled control siRNA (Cont.). At 16 h post-transfection,
the culture medium was replaced with fresh medium containing
JCV and, after 8 h of exposure to JCV, viral medium was removed
by aspiration, cells were washed once and fresh medium was
added. Four days post-transfection (3 days after JCV exposure),
nuclear fractions were prepared for use in Western blot experi-
ments with anti-NF-1A, anti-VP-1 and anti-b-actin antibodies.
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decrease in the level of NF-1A protein without affecting the
mRNA level. This reduction in NF-1A protein was
accompanied by an increase in JCV multiplication, as
measured by Western blot (Fig. 3a) as well as immuno-
fluorescence experiments (Fig. 3b). Taken together, our
data demonstrate that any means of reducing the
abundance of NF-1A protein in JCV-non-permissive cells
leads to an increase in JCV multiplication (Fig. 3c).
The molecular regulation of JCV expression limits the
range of cell types that can serve as sites of JCV latency,
reactivation and virion multiplication (Messam et al.,
2003). The range of cells that support JCV expression is
controlled, at least in part, by nucleotide sequences present
in the viral promoter/enhancer (Amemiya et al., 1992).
While the JCV promoter contains binding sites for many
nuclear transcription factors, the NF-1-binding site has
shown to be critical for JCV multiplication (Amemiya et al.,
1992). Many JCV-susceptible cells showed higher levels of
NF-1X protein expression, which implies the positive
activation of JCV genes by NF-1X. Our observation of
higher levels of expression of NF-1A protein in JCV-non-
susceptible cells prompted us to manipulate NF-1A protein
levels and to observe that a reduction in the level of NF-1A
protein led to an increase in JCV multiplication.
Even though the four NF-1 genes are expressed in broadly
overlapping patterns in different cell types, there are
apparently unique mechanisms for expression of individual
members of the NF-1 family. Since all NF-1 proteins bind
to the same DNA binding region but differ in their
promoter-specific activation and repression of transcrip-
tion, the association of NF-1 proteins with the JCV DNA
may be proportionate to the availability of an individual
member of the NF-1 family. Our study shows that NF-1A
and NF-1B proteins are abundant in JCV-non-susceptible
progenitor cells. During the differentiation into JCV-
susceptible PDA, the levels of NF-1A and NF-1B protein
decreased significantly. Also, our anchored-JCV–promoter
assay using the progenitor and PDA nuclear extract showed
association of NF-1A, NF-1B or NF-1X in proportion to
the level of protein (not shown). Hence, we assumed that
binding of NF-1A or NF-1B from the (JCV-non-suscept-
ible) progenitor cells at the JCV promoter might act as a
transcriptional repressor of JCV-encoded gene expression.
This is confirmed by our results, which also indicate that a
reduction of the level of NF-1A protein in progenitor cells
Fig. 3. Effect of miR-223 on JCV multiplica-
tion. Progenitors were transfected with hsa-
miR-223 or with control microRNA. At 16 h
post-transfection, the culture medium was
replaced with fresh medium containing JCV
and, after 8 h exposure to JCV, viral medium
was removed by aspiration, cells were washed
once and fresh medium was added. (a) Four
days post-transfection (3 days after JCV expo-
sure), nuclear fractions were prepared for use
in Western blot experiments with anti-VP-1,
anti-NF-1A and anti-b-actin antibodies. (b)
Four days post-transfection (3 days after JCV
exposure), cells were fixed, permeabilized and
stained with anti-VP-1 (red) and DAPI (blue).
(c) Schematic representation of the relation-
ship between the level of NF-1A and JCV
multiplication. NF-1A siRNA decreases the
level of NF-1A mRNA and thereby the level of
protein. hsa-miR-223 acts on the 39UTR of the
NF-1A mRNA and decreases the level of NF-
1A protein without affecting the level of mRNA.
The presence of NF-1-class proteins leads to
proportionate binding at the JCV promoter.
Higher levels of NF-1X/B lead to an increase in
NF-1X/B binding at the JCV promoter, thereby
increasing JCV multiplication. The higher level
of NF-1A leads to an increase in NF-1A at the
JCV promoter, thereby decreasing JCV mul-
tiplication. Reducing the level of NF-1A protein
by any means leads to an increase in JCV
multiplication.
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extend an earlier report that TGF-b1 increased JCV
multiplication in progenitor cells, we observed a decrease
in NF-1A levels after TGF-b1 treatment. There was,
however, no increase in the level of NF-1X protein.
Since the reduction of the level of NF-1A protein by siRNA
led to an increase in NF-1B protein as well as JCV
susceptibility, a proactive role of NF-1B was considered.
However, a reduction of the level of NF-1B protein by
siRNA was also associated with an increase in NF-1A and a
subsequent decrease in JCV susceptibility. To overcome
this reciprocal effect, we transfected progenitor cells with
NF-1B-encoding plasmids, and found that overexpression
of NF-1B protein did not lead to JCV multiplication (not
shown). The reduction of levels of NF-1A protein during
the differentiation of progenitor into PDA that leads to
JCV susceptibility suggests that progenitor cells, with
higher levels of NF-1A, experience a negative regulatory
effect of NF-1A on JCV gene transcription. The promoters
of several genes have been shown to be positively or
negatively regulated by NF-1 protein; in particular, NF-1A-
mediated transcriptional suppression of many genes has
been reported (Wong et al., 2007).
Furthermore, HeLa cells, which do not show JCV
susceptibility, also express higher levels of NF-1A protein.
Significantly, the addition of TGF-b1 resulted in JCV
activity in HeLa cells, which do not normally support JCV
activity. This increase in JCV activity was also associated
with a decrease in NF-1A protein. Further, these results
raise the possibility that, even though specific cellular
receptors are important for JCV internalization, regulatory
factors that act at the nuclear level are central to JCV
multiplication. The observation that JCV-non-permissive
cells, which express high levels of NF-1A, could also be
infected with JCV by reducing the level of NF-1A protein
supports the negative regulatory role of NF-1A on JCV
multiplication. Our results show the important cell-specific
regulatory mechanisms of NF-1A proteins in the control of
JCV multiplication.
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